PA: CoJourney Inc. Secures $30 Million Financing and Announces Expansion of US Operations

Pennsylvania-based CoJourney Inc. a global innovator in manufacturing and development of cell and gene therapies has completed a $30 million Series A financing and expansion of its US organization and commercial manufacturing capabilities. This funding round was led by Legend Capital and supported by GL Ventures, Legend Star Investment Management and Lake Bleu Capital.

CoJourney has developed high efficiency processes to support end-to-end custom development and manufacturing for genetic medicines, including plasmids, viral vectors, and mRNA. The company has built 130,000 square foot state-of-the-art cGMP manufacturing facilities that include 500L and 2,000L disposable bioreactors for viral vectors and 30L disposable fermenters for plasmids.

CoJourney’s unique value proposition is driven by a proprietary technology platform and robust and scalable processes, specifically tailored to meet the rigorous demands of commercial-scale manufacturing of genetic medicines. The management team has over 15 years of deep operational experience in cell and gene therapy manufacturing globally and is able to leverage this expertise to expedite production of the highest quality materials for clients CoJourney has established a strong track record of successfully delivering high-quality genetic medicines, viral vectors and plasmids to customers and supporting them through the entire regulatory process, ultimately enabling clients to obtain approval for Investigational New Drug (IND) applications in the United States and globally.

“I am proud of the highly innovative CDMO platform that CoJourney has built. Our streamlined manufacturing processes and state of the art quality systems and industry-leading cost structure will allow us to deliver the highest purity products to our clients with unprecedented turnaround times and cost structure. We believe this is the new model for cell and gene therapy CDMOs,” stated Lijun Wang, CEO, CoJourney Inc. “We are now at a pivotal stage in our company’s journey where we can become true strategic partners for our clients, helping them in their journey to advance innovative genetic medicines from early product development to clinical trial volumes and commercial scale manufacturing. We truly believe that we are embarking on a “co-journey” with our clients.